|
1
|
Rudometova NB, Fando AA, Kisakova LA, Kisakov DN, Borgoyakova MB, Litvinova VR, Yakovlev VA, Tigeeva EV, Vahitov DI, Sharabrin SV, Shcherbakov DN, Evseenko VI, Ivanova KI, Gudymo AS, Ilyicheva TN, Marchenko VY, Ilyichev AA, Rudometov AP, Karpenko LI. Immunogenic and Protective Properties of Recombinant Hemagglutinin of Influenza A (H5N8) Virus. Vaccines (Basel) 2024; 12:143. [PMID: 38400127 PMCID: PMC10893068 DOI: 10.3390/vaccines12020143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 01/23/2024] [Accepted: 01/27/2024] [Indexed: 02/25/2024] Open
Abstract
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus. The results demonstrated that both immunogens induced a specific antibody response as determined by ELISA. Virus neutralization assay revealed that sera of immunized animals were able to neutralize A/turkey/Stavropol/320-01/2020 (H5N8) influenza virus-the average neutralizing titer was 2560. Immunization with both recombinant HA/H5 hemagglutinin and inactivated virus gave 100% protection against lethal H5N8 virus challenge. This study shows that recombinant HA (H5N8) protein may be a useful antigen candidate for developing subunit vaccines against influenza A (H5N8) virus with suitable immunogenicity and protective efficacy.
Collapse
Affiliation(s)
- Nadezhda B. Rudometova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Anastasia A. Fando
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Lyubov A. Kisakova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Denis N. Kisakov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Mariya B. Borgoyakova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Victoria R. Litvinova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Vladimir A. Yakovlev
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Elena V. Tigeeva
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Danil I. Vahitov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Sergey V. Sharabrin
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Dmitriy N. Shcherbakov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Veronika I. Evseenko
- Institute of Solid State Chemistry and Mechanochemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Novosibirsk Region, Russia;
| | - Ksenia I. Ivanova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Andrei S. Gudymo
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Tatiana N. Ilyicheva
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Vasiliy Yu. Marchenko
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Alexander A. Ilyichev
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Andrey P. Rudometov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Larisa I. Karpenko
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| |
Collapse
|
|
2
|
Rudometova NB, Rudometov AP, Fando AA, Ushkalenko ND, Shcherbakov DN, Karpenko LI. Production and Study of Immunochemical Properties of Stabilized Env Trimer of Recombinant Form CRF63_02A6 of HIV-1. Bull Exp Biol Med 2023; 176:96-100. [PMID: 38093074 DOI: 10.1007/s10517-023-05978-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Indexed: 12/19/2023]
Abstract
Stabilized trimers of the HIV-1 envelope glycoprotein Env are capable of inducing a potent and sustained broadly neutralizing antibody response in laboratory animals and therefore are attractive targets for anti-HIV vaccine development. In this work, a stable producer of the trimer Env recombinant form CRF63_02A6 of HIV-1 was derived from the CHO-K1 cell line. Using immunochemical assays, the trimers synthesized in CHO-K1 cells were shown to be recognized by both monoclonal broadly neutralizing antibodies and sera from HIV-positive patients. The resulting trimers of the recombinant form CRF63_02A6 of HIV-1 can be used both for structural studies and as a candidate vaccine immunogen against HIV-1.
Collapse
Affiliation(s)
- N B Rudometova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
| | - A P Rudometov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A A Fando
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - N D Ushkalenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - D N Shcherbakov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| |
Collapse
|
|
3
|
Fomenko VV, Rudometova NB, Yarovaya OI, Rogachev AD, Fando AA, Zaykovskaya AV, Komarova NI, Shcherbakov DN, Pyankov OV, Pokrovsky AG, Karpenko LI, Maksyutov RA, Salakhutdinov NF. Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 Viruses. Molecules 2022; 27:295. [PMID: 35011529 PMCID: PMC8746574 DOI: 10.3390/molecules27010295] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 12/30/2021] [Accepted: 12/30/2021] [Indexed: 02/04/2023] Open
Abstract
When developing drugs against SARS-CoV-2, it is important to consider the characteristics of patients with different co-morbidities. People infected with HIV-1 are a particularly vulnerable group, as they may be at a higher risk than the general population of contracting COVID-19 with clinical complications. For such patients, drugs with a broad spectrum of antiviral activity are of paramount importance. Glycyrrhizinic acid (Glyc) and its derivatives are promising biologically active compounds for the development of such broad-spectrum antiviral agents. In this work, derivatives of Glyc obtained by acylation with nicotinic acid were investigated. The resulting preparation, Glycyvir, is a multi-component mixture containing mainly mono-, di-, tri- and tetranicotinates. The composition of Glycyvir was characterized by HPLC-MS/MS and its toxicity assessed in cell culture. Antiviral activity against three strains of SARS-CoV-2 was tested in vitro on Vero E6 cells by MTT assay. Glycyvir was shown to inhibit SARS-CoV-2 replication in vitro (IC502-8 μM) with an antiviral activity comparable to the control drug Remdesivir. In addition, Glycyvir exhibited marked inhibitory activity against HIV pseudoviruses of subtypes B, A6 and the recombinant form CRF63_02A (IC50 range 3.9-27.5 µM). The time-dependence of Glycyvir inhibitory activity on HIV pseudovirus infection of TZM-bl cells suggested that the compound interfered with virus entry into the target cell. Glycyvir is a promising candidate as an agent with low toxicity and a broad spectrum of antiviral action.
Collapse
Affiliation(s)
- Vladislav V. Fomenko
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
| | - Nadezhda B. Rudometova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Olga I. Yarovaya
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Artem D. Rogachev
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Anastasia A. Fando
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Nina I. Komarova
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Andrey G. Pokrovsky
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Rinat A. Maksyutov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Nariman F. Salakhutdinov
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| |
Collapse
|
|
4
|
Rudometova NB, Shcherbakova NS, Shcherbakov DN, Mishenova EV, Delgado E, Ilyichev AA, Karpenko LI, Thomson MM. Genetic Diversity and Drug Resistance Mutations in Reverse Transcriptase and Protease Genes of HIV-1 Isolates from Southwestern Siberia. AIDS Res Hum Retroviruses 2021; 37:716-723. [PMID: 33677988 DOI: 10.1089/aid.2020.0225] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The analysis of a pol gene fragment encoding protease and part of reverse transcriptase was carried out for 55 sera collected in 2016 and 2018 from HIV-1-infected patients diagnosed in 2014-2018 living in the south of Western Siberia, Russia: Altai Territory (n = 11), Republic of Altai (n = 15), Kemerovo region (n = 18), and Novosibirsk region (n = 11). CRF63_02A was the dominant genetic form (>70%) in the Altai Territory and Kemerovo and Novosibirsk regions, with subsubtype A6 comprising <30% of samples. In the Altai Republic, subsubtype A6 was predominant (53%), with 33% of viruses belonging to CRF63_02A. Four CRF63_02A/A6 unique recombinant forms were identified in the Altai Territory, Kemerovo Region, and the Altai Republic. A majority (11 of 15) of CRF63_02A viruses from Kemerovo were grouped in a cluster. Antiretroviral (ARV) drug resistance mutations were found in 6 (14%) of 43 drug-naive patients. This study provides new insights in HIV-1 molecular epidemiology and prevalence of transmitted ARV drug resistance mutations in Southwestern Siberia.
Collapse
Affiliation(s)
- Nadezhda B. Rudometova
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Nadezhda S. Shcherbakova
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Dmitry N. Shcherbakov
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Elena V. Mishenova
- Budgetary Health Care Institution of the Republic of Altai “Center for the Prevention and Control of AIDS”, Gorno-Altaysk, Russia
| | - Elena Delgado
- HIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
| | - Alexander A. Ilyichev
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Larisa I. Karpenko
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Michael M. Thomson
- HIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
|
5
|
Starostina EV, Sharabrin SV, Antropov DN, Stepanov GA, Shevelev GY, Lemza AE, Rudometov AP, Borgoyakova MB, Rudometova NB, Marchenko VY, Danilchenko NV, Chikaev AN, Bazhan SI, Ilyichev AA, Karpenko LI. Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens. Vaccines (Basel) 2021; 9:452. [PMID: 34063689 PMCID: PMC8147809 DOI: 10.3390/vaccines9050452] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 04/15/2021] [Accepted: 04/29/2021] [Indexed: 01/08/2023] Open
Abstract
Nucleic acid-based influenza vaccines are a promising platform that have recently and rapidly developed. We previously demonstrated the immunogenicity of DNA vaccines encoding artificial immunogens AgH1, AgH3, and AgM2, which contained conserved fragments of the hemagglutinin stem of two subtypes of influenza A-H1N1 and H3N2-and conserved protein M2. Thus, the aim of this study was to design and characterize modified mRNA obtained using the above plasmid DNA vaccines as a template. To select the most promising protocol for creating highly immunogenic mRNA vaccines, we performed a comparative analysis of mRNA modifications aimed at increasing its translational activity and decreasing toxicity. We used mRNA encoding a green fluorescent protein (GFP) as a model. Eight mRNA-GFP variants with different modifications (M0-M7) were obtained using the classic cap(1), its chemical analog ARCA (anti-reverse cap analog), pseudouridine (Ψ), N6-methyladenosine (m6A), and 5-methylcytosine (m5C) in different ratios. Modifications M2, M6, and M7, which provided the most intensive fluorescence of transfected HEK293FT cells were used for template synthesis when mRNA encoded influenza immunogens AgH1, AgH3, and AgM2. Virus specific antibodies were registered in groups of animals immunized with a mix of mRNAs encoding AgH1, AgH3, and AgM2, which contained either ARCA (with inclusions of 100% Ψ and 20% m6A (M6)) or a classic cap(1) (with 100% substitution of U with Ψ (M7)). M6 modification was the least toxic when compared with other mRNA variants. M6 and M7 RNA modifications can therefore be considered as promising protocols for designing mRNA vaccines.
Collapse
Affiliation(s)
- Ekaterina V. Starostina
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Sergei V. Sharabrin
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Denis N. Antropov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Grigory A. Stepanov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Georgiy Yu. Shevelev
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Anna E. Lemza
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Nadezhda B. Rudometova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Vasiliy Yu. Marchenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Natalia V. Danilchenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Anton N. Chikaev
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia;
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| |
Collapse
|
|
6
|
Karpenko LI, Rudometov AP, Sharabrin SV, Shcherbakov DN, Borgoyakova MB, Bazhan SI, Volosnikova EA, Rudometova NB, Orlova LA, Pyshnaya IA, Zaitsev BN, Volkova NV, Azaev MS, Zaykovskaya AV, Pyankov OV, Ilyichev AA. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. Vaccines (Basel) 2021; 9:76. [PMID: 33494530 PMCID: PMC7910849 DOI: 10.3390/vaccines9020076] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 01/15/2021] [Accepted: 01/19/2021] [Indexed: 12/12/2022] Open
Abstract
One of the key stages in the development of mRNA vaccines is their delivery. Along with liposome, other materials are being developed for mRNA delivery that can ensure both the safety and effectiveness of the vaccine, and also facilitate its storage and transportation. In this study, we investigated the polyglucin:spermidine conjugate as a carrier of an mRNA-RBD vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The conditions for the self-assembling of mRNA-PGS complexes were optimized, including the selection of the mRNA:PGS charge ratios. Using dynamic and electrophoretic light scattering it was shown that the most monodisperse suspension of nanoparticles was formed at the mRNA:PGS charge ratio equal to 1:5. The average hydrodynamic particles diameter was determined, and it was confirmed by electron microscopy. The evaluation of the zeta potential of the investigated complexes showed that the particles surface charge was close to the zero point. This may indicate that the positively charged PGS conjugate has completely packed the negatively charged mRNA molecules. It has been shown that the packaging of mRNA-RBD into the PGS envelope leads to increased production of specific antibodies with virus-neutralizing activity in immunized BALB/c mice. Our results showed that the proposed polycationic polyglucin:spermidine conjugate can be considered a promising and safe means to the delivery of mRNA vaccines, in particular mRNA vaccines against SARS-CoV-2.
Collapse
Affiliation(s)
- Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Sergei V. Sharabrin
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Nadezhda B. Rudometova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Lyubov A. Orlova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Inna A. Pyshnaya
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia;
| | - Boris N. Zaitsev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Natalya V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Mamedyar Sh. Azaev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| |
Collapse
|
|
7
|
Rudometov AP, Chikaev AN, Rudometova NB, Antonets DV, Lomzov AA, Kaplina ON, Ilyichev AA, Karpenko LI. Artificial Anti-HIV-1 Immunogen Comprising Epitopes of Broadly Neutralizing Antibodies 2F5, 10E8, and a Peptide Mimic of VRC01 Discontinuous Epitope. Vaccines (Basel) 2019; 7:vaccines7030083. [PMID: 31390770 PMCID: PMC6789618 DOI: 10.3390/vaccines7030083] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 07/24/2019] [Accepted: 07/30/2019] [Indexed: 01/05/2023] Open
Abstract
The construction of artificial proteins using conservative B-cell and T-cell epitopes is believed to be a promising approach for a vaccine design against diverse viral infections. This article describes the development of an artificial HIV-1 immunogen using a polyepitope immunogen design strategy. We developed a recombinant protein, referred to as nTBI, that contains epitopes recognized by broadly neutralizing HIV-1 antibodies (bNAbs) combined with Th-epitopes. This is a modified version of a previously designed artificial protein, TBI (T- and B-cell epitopes containing Immunogen), carrying four T- and five B-cell epitopes from HIV-1 Env and Gag proteins. To engineer the nTBI molecule, three B-cell epitopes of the TBI protein were replaced with the epitopes recognized by broadly neutralizing HIV-1 antibodies 10E8, 2F5, and a linear peptide mimic of VRC01 epitope. We showed that immunization of rabbits with the nTBI protein elicited antibodies that recognize HIV-1 proteins and were able to neutralize Env-pseudotyped SF162.LS HIV-1 strain (tier 1). Competition assay revealed that immunization of rabbits with nTBI induced mainly 10E8-like antibodies. Our findings support the use of nTBI protein as an immunogen with predefined favorable antigenic properties.
Collapse
Affiliation(s)
- Andrey P Rudometov
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia.
| | - Anton N Chikaev
- Institute of Molecular and Cellular Biology of the Siberian Branch of the Russian Academy of Sciences, 8/2 Lavrentiev Avenue Novosibirsk, Novosibirsk 630090, Russia.
| | - Nadezhda B Rudometova
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Denis V Antonets
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander A Lomzov
- Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, 8 Lavrentiev Avenue, Novosibirsk 630090, Russia
| | - Olga N Kaplina
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander A Ilyichev
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Larisa I Karpenko
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia.
| |
Collapse
|